CoChat

Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3

Abdollahi, Pegah, Vandsemb, Esten N., Hjort, Magnus A., Misund, Kristine, Holien, Toril, Sponaas, Anne-Marit, Rø, Torstein B., Slørdahl, Tobias S., Børset, Magne · 2017 · Molecular Cancer Research

Published version of a preprint

Cited by 17

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Phosphatase of regenerating liver-3 (PTP4A3/PRL-3) is a dual-specificity phosphatase that is upregulated in various types of cancers and is related to poor prognosis and aggressive tumor behavior. The expression level of PRL-3 is elevated in response to several antiapoptotic cytokines, including IL6, in cancer cells from patients with multiple myeloma (MM) and can promote survival and migration. Here, it is demonstrated that PRL-3 activates Src kinase in the IL6-dependent MM cell line INA-6. Inhibition of PRL-3 by a small-molecule inhibitor of PRL-3 or by shRNA resulted in inactivation of Src. In addition to activation of Src, PRL-3 also activated the Src family kinase (SFK) members LYN and HCK in INA-6 cells. Forced expression of catalytically inactive mutant PRL-3 decreased the activation of these three SFK members while the total level of HCK and FYN remained elevated. Inhibitors of Src increased sensitivity of cells overexpressing PRL-3 to the PRL-3 inhibitor through joint downregulation of both PRL-3 and Mcl-1. In conclusion, PRL-3 protected MM cells against apoptosis by dysregulating both the total levels and the activation levels of specific SFK members that are important for IL6 signal transduction in MM cells. Eventually, this led to increased levels of Mcl-1. Implications: This study suggests PRL-3 and SFKs are key mediators of the IL6-driven signaling events and points to both PRL-3 and SFK members as potential targets for treatment of MM. Mol Cancer Res; 15(1); 69–77. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-16-0212

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 35

  1. Chatterjee, 2004, Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells, Blood, 104, 3712, 10.1182/blood-2004-04-1670 · DOI · Paper page
  2. Andrews, 2013, Multiple myeloma: the bone marrow microenvironment and its relation to treatment, Br J Biomed Sci, 70, 110, 10.1080/09674845.2013.11669945 · DOI
  3. Mahindra, 2010, Multiple myeloma: biology of the disease, Blood Reviews, 24, S5, 10.1016/S0268-960X(10)70003-5 · DOI
  4. Frassanito, 2001, Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis, Blood, 97, 483, 10.1182/blood.V97.2.483 · DOI · Paper page
  5. Brocke-Heidrich, 2004, Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation, Blood, 103, 242, 10.1182/blood-2003-04-1048 · DOI · Paper page
  6. Ogata, 1997, IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade, J Immunol, 159, 2212, 10.4049/jimmunol.159.5.2212 · DOI · Paper page
  7. Sen, 2011, Regulation of SRC family kinases in human cancers, J Signal Transduct, 2011, 865819, 10.1155/2011/865819 · DOI · Paper page
  8. Parsons, 2004, Src family kinases, key regulators of signal transduction, Oncogene, 23, 7906, 10.1038/sj.onc.1208160 · DOI · Paper page
  9. Ishikawa, 2003, Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules, Int J Hematol, 78, 95, 10.1007/BF02983376 · DOI
  10. Sicheri, 1997, Crystal structure of the Src family tyrosine kinase Hck, Nature, 385, 602, 10.1038/385602a0 · DOI · Paper page
  11. Fagerli, 2008, Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells, Blood, 111, 806, 10.1182/blood-2007-07-101139 · DOI
  12. Campbell, 2014, Phosphatase of regenerating liver: a novel target for cancer therapy, Expert Opin Ther Tar, 18, 555, 10.1517/14728222.2014.892926 · DOI
  13. Hu, 2013, Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis, PLoS One, 8, e76927, 10.1371/journal.pone.0076927 · doi:10.1371/journal.pone.0076927
  14. Dong, 2016, PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma, J Oral Pathol Med, 45, 111, 10.1111/jop.12331 · DOI
  15. Broyl, 2010, Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients, Blood, 116, 2543, 10.1182/blood-2009-12-261032 · DOI · Paper page
  16. Kobayashi, 2014, Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies, Cell Cycle, 13, 2827, 10.4161/15384101.2014.954448 · DOI
  17. Zhou, 2011, PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy, PLoS One, 6, e19798, 10.1371/journal.pone.0019798 · DOI
  18. Zhou, 2012, The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia, Mol Cancer, 11, 72, 10.1186/1476-4598-11-72 · DOI
  19. Slordahl, 2016, The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells, Oncotarget, 7, 27295, 10.18632/oncotarget.8422 · DOI
  20. Hausherr, 2007, Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases, Oncogene, 26, 4987, 10.1038/sj.onc.1210306 · DOI
  21. Hallek, 1997, Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines, Exp Hematol, 25, 1367
  22. Walls, 2013, Phosphatase of regenerating liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction, Mol Cell Proteomics, 12, 3759, 10.1074/mcp.M113.028886 · DOI
  23. Zimmerman, 2014, Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility, J Biol Chem, 289, 5904, 10.1074/jbc.M113.480038 · DOI
  24. Fiordalisi, 2013, Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion, Plos One, 8, 10.1371/journal.pone.0064309 · DOI · Paper page
  25. Liang, 2007, PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation, J Biol Chem, 282, 5413, 10.1074/jbc.M608940200 · DOI · Paper page
  26. Liang, 2008, Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase, J Biol Chem, 283, 10339, 10.1074/jbc.M708285200 · DOI
  27. Tsubaki, 2014, By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells, Leuk Res, 38, 121, 10.1016/j.leukres.2013.10.017 · DOI
  28. Coluccia, 2008, Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib, Blood, 112, 1346, 10.1182/blood-2007-10-116590 · DOI
  29. Heusschen, 2016, SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma, Oncotarget, 7, 30712, 10.18632/oncotarget.8750 · DOI
  30. Geahlen, 2004, Molecular interdiction of Src-family kinase signaling in hematopoietic cells, Oncogene, 23, 8024, 10.1038/sj.onc.1208078 · DOI
  31. Ishikawa, 2002, Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6, Blood, 99, 2172, 10.1182/blood.V99.6.2172 · DOI
  32. Ishikawa, 2003, Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation, Leuk Lymphoma, 44, 1477, 10.3109/10428190309178767 · DOI
  33. Podar, 2004, Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells, J Biol Chem, 279, 21658, 10.1074/jbc.M305783200 · DOI
  34. Chandrasekharan, 2002, Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak, Mol Cell Biol, 22, 5235, 10.1128/MCB.22.14.5235-5247.2002 · DOI
  35. Calautti, 1998, Tyrosine phosphorylation and src family kinases control keratinocyte cell-cell adhesion, J Cell Biol, 141, 1449, 10.1083/jcb.141.6.1449 · DOI · Paper page

Cited by

See all 17

Metadata

Authors
Abdollahi, P., Vandsemb, E. N., Hjort, M. A., Misund, K., Holien, T., Sponaas, A.-M., Rø, T. B., Slørdahl, T. S., & Børset, M.
Affiliations
1Department of Cancer Research and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Venue
Molecular Cancer Research
Published
2017-01-01
Volume
15
Issue
1
Pages
69-77
ISSN
  • 1541-7786
  • 1557-3125
Cited by
17
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-16-0212
The paper
Abdollahi, P., Vandsemb, E. N., Hjort, M. A., Misund, K., Holien, T., Sponaas, A.-M., Rø, T. B., Slørdahl, T. S., & Børset, M. (2017). Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-16-0212

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.